Nanopublication: RA9tplnxsJ

Full identifier: http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RA9tplnxsJ comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tplnxsJ...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tplnxsJ... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-15T18:17:22.636+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tplnxsJ... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tplnxsJ... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tplnxsJ... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tplnxsJ...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA9tplnxsJ... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tplnxsJ...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 15 Jun 2021, 16:17:22 UTC

show references